Ann: Half Yearly Report and Accounts, page-6

"During the second half of the financial year, the Company will be focused on:
 Continuing detailed supplementary analyses of samples from the Phase 2 HIV-1 trial seeking to furthercharacterise the clinical efficacy of BIT225.
 Ongoing discussions and sharing of data from the HIV-1 Phase 2 clinical trial with potential partners.
 Undertaking additional in vitro cell-based preclinical testing of compounds for the HBV program, includingscreening of newly designed and synthesized compounds for potential anti-HBV activity.
 Continued testing of Biotron compounds for activity against other key commercially relevant virus targets."